Growth-focused UK equity managers have joined their income peers in backing pharmaceuticals as deals both real and rumoured send shares rocketing.
A multi-billion pound asset exchange between GlaxoSmithKline and Swiss peer Novartis, announced last Tuesday, was followed by AstraZeneca revealing it too is considering spinning off businesses worth $15bn as sector giants begin to focus on core businesses. Both Astra and Glaxo saw their shares jump as a result, with Astra having also seen a 9% jump on rumours US rival Pfizer has considered a $100bn bid for the company. Astra shares then rose another 15% this morning after Pfizer revealed it had unsuccessfully attempted to renew discussions this weekend over combining the businesses....
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
